- Home
- SES vs PRTA Comparison
SES vs PRTA Comparison
Compare SES & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SES
- PRTA
- Stock Information
- Founded
- SES 2012
- PRTA 2012
- Country
- SES United States
- PRTA Ireland
- Employees
- SES N/A
- PRTA N/A
- Industry
- SES Auto Parts:O.E.M.
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- SES Consumer Discretionary
- PRTA Health Care
- Exchange
- SES Nasdaq
- PRTA Nasdaq
- Market Cap
- SES 384.0M
- PRTA 472.1M
- IPO Year
- SES N/A
- PRTA N/A
- Fundamental
- Price
- SES $1.12
- PRTA $8.20
- Analyst Decision
- SES Hold
- PRTA Buy
- Analyst Count
- SES 3
- PRTA 10
- Target Price
- SES $1.50
- PRTA $14.86
- AVG Volume (30 Days)
- SES 5.6M
- PRTA 1.2M
- Earning Date
- SES 08-04-2025
- PRTA 08-04-2025
- Dividend Yield
- SES N/A
- PRTA N/A
- EPS Growth
- SES N/A
- PRTA N/A
- EPS
- SES N/A
- PRTA N/A
- Revenue
- SES $11,360,000.00
- PRTA $10,341,000.00
- Revenue This Year
- SES $883.92
- PRTA N/A
- Revenue Next Year
- SES $159.98
- PRTA $389.77
- P/E Ratio
- SES N/A
- PRTA N/A
- Revenue Growth
- SES N/A
- PRTA N/A
- 52 Week Low
- SES $0.20
- PRTA $4.32
- 52 Week High
- SES $2.53
- PRTA $22.83
- Technical
- Relative Strength Index (RSI)
- SES 51.03
- PRTA 58.73
- Support Level
- SES $1.09
- PRTA $8.05
- Resistance Level
- SES $1.22
- PRTA $8.73
- Average True Range (ATR)
- SES 0.07
- PRTA 0.38
- MACD
- SES -0.00
- PRTA -0.05
- Stochastic Oscillator
- SES 55.32
- PRTA 47.62
About SES SES AI Corporation
SES AI Corp is a developer and manufacturer of high-performance, AI-enhanced Lithium-Metal (Li-Metal) and Lithium-ion (Li-ion) rechargeable battery technologies for electric vehicles (EVs), Urban Air Mobility (UAM), drones, robotics, Battery Energy Storage Systems (BESS) and other applications. It includes Software and Hardware products that are EV, UAM, Drone, Molecular Universe, and Avatar.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.